Abnormal activation of the RAF/
MEK/ERK signaling pathway has been observed in
breast cancer. Thus, a number of
MEK inhibitors have been designed as one treatment option for
breast cancer. Although some studies have found that these
MEK inhibitors inhibit the growth of a variety of human
cancer cells, some trials have shown that the use of
MEK inhibitors as a treatment for
breast cancer does not adequately improve survival for unknown reasons. In the present study,
MEK inhibitor
PD98059 was used to evaluate its anticancer effects on human
breast cancer MCF-7 and MDA-MB-231 cells and to explore the possible mechanism of action. Our results revealed that
MEK inhibitor
PD98059 exhibited antiproliferative effects in a dose- and time-dependent manner in MCF-7 and MDA-MB-231
breast cancer cells. Conversely, incubation of MCF-7 and MDA-MB-231 cells with
PD98059 promoted their migration. Further investigation disclosed that the enhanced ability of migration promoted by
PD98059 was dependent on β-
catenin nuclear translocation in the MCF-7 and MDA-MB‑231 cells. Subsequent experiments documented that activation of EGFR signaling induced by
PD98059 increased the amount of β-
catenin in the nucleus. Taken together, our findings may elucidate a possible mechanism explaining the ineffectiveness of
MEK inhibitors in
breast cancer treatment and improve our understanding of the role of
MEK in
cancer.